Head-to-head · WeighScore
Marek Health vs Onyx Weight Loss
The verdict
Marek Health takes it — 66.9/100 to 58.8/100.
Marek Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Marek Health is a performance-focused telehealth platform pairing US clients with partnered physicians and health coaches for GLP-1 weight-loss therapy (semaglutide and tirzepatide), comprehensive lab…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Marek Health | Onyx Weight Loss |
|---|---|---|
| WeighScore | 66.9/100 | 58.8/100 |
| Grade | C | C |
| Scorecard rank | #173 | #359 |
| Semaglutide | Not disclosed | $228/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $280/mo (starting dose, compounded) |
| Coverage | All 50 states | 8 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #173 · C
Strengths
- Lab panels are core: initial comprehensive labs + 6–12 week follow-up + ongoing every 6 months — rare among GLP-1 providers
- Dedicated Health Coach paired with each client alongside partnered licensed physician as standard Proactive Care Team
- All 50 US states served; 100% telehealth with routine physician check-ins every 6 months built into the program
- Human optimization framing attracts pragmatic patients; partnered physicians selected for data-driven, high-leverage mindset
- No set subscription plan — custom protocol built around client health goals with option to cancel anytime
Where it loses points
- Pricing fully gated — no published rates; intake assessment required before quotes, limiting upfront comparison shopping
- Annual in-person physical required from own PCP or urgent care (every 12 months) — not provided by Marek Health
- No LegitScript certification found; platform explicitly disclaims being a healthcare clinic, which reduces regulatory trust signals
- Weight loss is one of many services alongside TRT, hair, brain focus, sexual health — not a dedicated GLP-1 platform
- Compounded vs. brand medication details not disclosed publicly — medication type determined post-intake with partnered physician
Graded #359 · C
Strengths
- Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
- Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
- Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
- Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
- Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team
Where it loses points
- Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
- No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
- Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
- Labs not included or mentioned; no baseline bloodwork protocol published
- Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.